

Hospital water point-of-use filtration: A complementary strategy to reduce the risk of nosocomial infection

Girolamo A. Ortolano, PhD, Morven B. McAlister, PhD, Judy A. Angelbeck, PhD, Jeffrey Schaffer, DVM, Rosalind L. Russell, PhD, Elise Maynard, MS, and Barry Wenz, MD
East Hills, New York

Cholera, hepatitis and typhoid are well-recognized water-borne illnesses that take the lives of many every year in areas of uncontrollable flood, but far less attention is afforded to the allegedly safe potable water in affluent nations and the presumed healthful quality of water in communities and hospitals. Recent literature, however, points to increasing awareness of serious clinical sequelae particularly experienced by immunocompromised patients at high risk for disease and death from exposure to water-borne microbes in hospitals. This review reflects the literature indicting hospital water as an important source for nosocomial infections, examines patient populations at greatest risk, uncovers examples of failures in remedial water treatment methods and the reasons for them, and introduces point-of-use water filtration as a practical alternative or complementary component of an infection control strategy that may reduce the risk of nosocomial infections. (Am J Infect Control 2005;33:S1-19.)

Despite advances in health care and with total admissions remaining constant (Figure 1A), the rate of hospital-acquired (nosocomial) infections in the United States has actually increased over the 20-year period from 1975 to 1995 (Figure 1B).¹

Successful initiatives to shorten hospital length of stay (LOS) further confound assessment of the true incidence of nosocomial infections, because the incubation period may be longer than the average hospital LOS.¹ Among the types of nosocomial infections, pneumonia is a common cause of morbidity and mortality second only to urinary tract infections in frequency of occurrence and it ranks first among

nosocomial infections in critical care settings.² The added cost of infectious complications is estimated to range from \$15,275³ to \$38,656⁴ per infection.

Concern for the health and welfare of the patient should be the most important impetus to control nosocomial infections. Another factor includes cost pressures derived from increasingly scarce professional resources such as critical care physicians and nurses, which drive costs up as well as costly litigation, particularly evident in litigious societies.⁵ What proportion of these nosocomial infections may be attributable to hospital water? In a call to arms for physicians and infection control practitioners alike, it has been said that "Although numerous hospital sources cause nosocomial outbreaks, perhaps the most overlooked, important, and controllable source of nosocomial pathogens is hospital water."⁶

LEGIONELLA

An excellent example of the profound implications of water-borne nosocomial infection relate to recent observations of *Legionella*. *Legionella* species (*sp.*) are well recognized as water-borne microorganisms and were made infamous with the devastation of an American Legion Convention in a hotel in Philadelphia in 1976. Since then, its history as a water-borne mediator of morbidity has been reviewed both microbiologically⁷ and clinically.^{8,9} *Legionella sp.* have been isolated in as few as 1% to as many as 40% of cases of hospital-acquired pneumonia; consequently, underdiagnosis and underreporting are high with only 2-10% of estimated cases believed to be accurately reported.¹⁰

From the Pall Corporation, East Hills, New York.

This article is reprinted with permission from Ecosse Publishing Limited. The original citation information is: Ortolano GA, McAlister MB, Angelbeck JH, Schaffer J, Russell RL, Maynard E, Wenz B. Hospital water point-of-use filtration: a complementary strategy to reduce the risk of nosocomial infection. *Filtration* 2004;suppl 1:3-25. Requests for reprints of this article should be made directly to Ecosse Publishing Limited, PO Box 270, Waterlooville, Hampshire PO7 8ZU, UK. Tel/Fax: 0870 046 6494. E-mail: production@filtrationjournal.com.

Conflict of interest statement: All authors except Barry Wenz are employed by the Pall Corporation at which Girolamo A. Ortolano, PhD, is Vice President for Scientific Affairs; Morven B. McAlister, PhD, is Biopharmaceutical Sciences Manager in the Division of Scientific and Laboratory Services (SLS); Judy A. Angelbeck, PhD, is Senior Vice President for Technical Marketing; Jeffrey Schaffer, DVM, is SLS Staff Scientist; Rosalind L. Russell, PhD, is SLS Senior Staff Scientist; Elise Maynard, MS, is SLS Laboratory Manager; and Barry Wenz, MD, is a consultant to Pall Medical, serving as interim Medical Director.

0196-6553/\$30.00

© Ecosse Publishing Limited 2004.

doi:10.1016/j.ajic.2005.03.014




Fig 1. Nosocomial infections are a growing concern in US hospitals (adapted from Weinstein¹) (see also <http://www.cdc.gov/ncidod/eid/vol4no3/contents.htm>).

Transmission of *Legionella sp.* from hospital water can occur by inhalation of aerosolized microbes that are commonly generated during showering¹¹ or running bath water.¹² Equipment washed or rinsed with contaminated water can also confer infection.¹³

Hospital water supplies are frequently contaminated with *Legionella sp.*¹⁴⁻¹⁶ and recent evidence of nosocomial infection is also available¹⁷ making this microorganism one of current concern. In one study, 55% of transplant units in the United Kingdom tested positive for *Legionella*¹⁸ as well as 80% of 11 hospitals sampled in Italy.¹⁹ A hospital in Canada reported nearly 25% of the 2200 samples taken over 4 years were positive for *Legionella* with some locations more problematic than others.²⁰

Interestingly, guidelines for the prevention of health-care-associated pneumonia include the routine culturing of water systems for *Legionella sp.* limited, however, to patient-care areas at high risk for infection.²¹ Despite this observation and with many regulations in place to support prevention and detection, a recent survey shows that "...only 5% of health care facilities have developed and implemented a waterborne pathogen risk management plan for building water systems."²² This underscores the perception by many that *Legionella sp.*, and to a greater extent other microbes, are not recognized for the dangers they present.

OTHER BACTERIA

Three major categories of water-borne nosocomial infectious organisms, including bacteria, mycobacterium and fungi have been delineated and are shown in Table 1 modified from Anaissie and co-workers.⁶ Many

of these organisms were shown to be resistant to antibiotics.⁶ Additional evidence was compiled by the authors suggestive of a causal relationship between contaminated hospital water and infectious complications. The causal relationship is supported by the use of antibiograms, serotyping or temporal association and supports the view that nosocomial infections may be derived from hospital water-borne microorganisms such as *Campylobacter*,²³ *Aeromonas*,²⁴ *Flavobacterium*, *Enterobacter*, *Serratia* and *Klebsiella sp.* Other literature reviews support these observations.^{25,26} Adding to the compendium is a recent report of a *Mycobacterium simiae* outbreak from contaminated hospital water²⁷ and *Mycobacterium* is frequently recovered from hospital water.²⁸

Pseudomonas is an organism that can cause serious nosocomial infection.²⁹ Stamm-Balderjahn³⁰ and co-workers, presenting at the Society for Healthcare in Epidemiology (SHEA) meeting in April 2004, reviewed the literature disclosing *Pseudomonads* as one of the most frequently reported pathogens concerning nosocomial outbreaks. The results (expressed as percent of total) are shown in Figure 2 and illustrate blood stream infections occurred most often and the most frequent environmental source reportedly is hospital water.

The timeliness and increasing awareness of the dangers of hospital water are reflected in the observations of clinicians at a hospital in Lebanon citing "...potentially the largest single-source nosocomial bloodstream infection outbreak ever reported, and the first report of an alcohol skin antiseptic contaminated by tap water as a source for nosocomial bacteremia."³¹ Moreover, the contribution of tap water and environmental surfaces towards bronchoscope and endoscope mediated transmission of antibiotic-resistant

Table I. Evidence correlating infection inpatients with microorganisms found in hospital water

Organism	Site of infection	Molecular-relatedness evidence	Number of reports
Bacteria			
<i>Pseudomonas aeruginosa</i>	Blood, CVC, lungs, peritoneum, sinuses, trachea, urine	PCR; DNA macrorestriction analysis, PFGE, ERIC-PCR, RAPD, DNA fingerprinting, DNA typing, serotyping, phage typing, serogrouping, genotyping, ExoA DNA probe, biotyping, electrophoretic esterase typing	10
<i>Stenotrophomonas maltophilia</i>	Blood, peritoneum, respiratory tract, skin, stools, throat, trachea, urine	PFGE, RAPD	4
<i>Serratia marcescens</i>	Eye, stools	PFGE	1
<i>Acinetobacter baumannii</i>	Skin, wound	PFGE, biotyping	1
<i>Aeromonas hydrophila</i>	Blood	electrophoretic esterase typing	1
<i>Chryseobacterium</i> species	Blood	AP-PCR	1
Mycobacterium			
<i>Mycobacterium avium</i>	Disseminated	PFGE	1
<i>Mycobacterium fortuitum</i>	Disseminated, respiratory tract, sputum, sternal wound infection wound	AP-PCR, PFGE, phenotype analysis, plasmid profiles,	4
<i>Mycobacterium xenopi</i>	Various, spine	PCR-based techniques, chromosomal restriction fragment patterns	2
<i>Mycobacterium kansasii</i>	Abscess, blood, bone, sputum, stomach, urine	RFLP, PFGE	1
<i>Mycobacterium chelonae</i>	Sternal wound infection, prosthetic valve	Electrophoresis of enzymes, plasmid profiling	1
Fungi			
<i>Fusarium solani</i>	Disseminated	RFLP, RAPD, IR-PCR	1
<i>Exophiala jeanselmaei</i>	Disseminated	RAPD	1
<i>Aspergillus fumigatus</i>	Lungs	PCR, SSPD	1

Adapted from Anaissie et al.⁶

CVC, central venous catheter; AP, arbitrarily primed; PCR, polymerase chain reaction; PFGE, pulse-field gel electrophoresis; ERIC, enterobacterial repetitive intergenic consensus sequencing; RAPD, random amplified polymorphic DNA; ExoA, exotoxin A; RFLP, restriction fragment-length polymorphism; AFLP, amplified fragment-length polymorphism; IR, interrepeat; SSPD, sequence-specific DNA primer analysis.

nosocomial *Pseudomonas aeruginosa* infections was reviewed recently, and a compelling argument for their role as a contributing factor in clinically important disease was provided.³²

MOLDS

Fungi including molds and yeasts were cultured from hospital water and their reported prevalence was quite high³³ and observed by others.^{34,35} Among 126 potable water samples, two-thirds of which came from

hospitals, molds were present in nearly 83% and yeasts from 11%. *Aspergillus* was recovered from 53, or a third, of the samples. Interestingly, a pattern emerged showing yeasts were correlated with coliforms, whereas filamentous fungi correlated more with total heterotrophic bacteria counts. Therefore, detection of elevated heterotrophic plate count might be a prognosticator of filamentous fungal infections.

Aspergillus species abound in the hospital setting and the rise in prevalence has startled some.³⁶ Molecular biology techniques applied to water and air-borne




Fig 2. Distribution of *Pseudomonas* nosocomial infections reported from 91 outbreaks over the period 1965-early 2004 (adapted from Stamm-Balderjahn et al³⁰). Abbreviations: UTI, urinary tract infections; SSI, surgical site infections.

Aspergillus confirm these as the source of infections in patients.³⁷ Recent studies were performed in a hematologic malignancy patient population immunocompromised by virtue of their disease or the chemotherapy treatment they require. Molds, including *Aspergillus*, were recovered from 70% of water samples, 22% of swabs from the plumbing and 83% of indoor air in over 1900 samples taken in a bone marrow transplant unit. Results of the study strongly suggest that the mold recovered from indoor air derives from aerosolization of the shower water.³⁸ These data support previously espoused views suggesting that re-aerosolization of mold from shower walls can occur and serve as a mechanism of infectivity.³⁹

VIRUSES

A number of viruses are known to be transmitted through water and most notable among them are rotavirus, para-rotavirus, reovirus (reoviridae), hepatitis A and E, and norovirus (formerly known as the Norwalk virus).⁴⁰ Water-borne hospital acquired viral infections are documented as well.^{41,42} However, since they cannot proliferate outside of a host, their numbers tend to be naturally lower than other microbes.

PROTOZOA

Community-acquired water-borne infections are well known, and caused by the protozoans, *Cryptosporidium* and *Giardia* where the former was popularized by an outbreak in Milwaukee, Wisconsin, in 1993 affecting over 400 thousand citizens.^{43,44} The fact that

these organisms can pass through treated water that meets quality standards suggests that these standards may be inadequate⁴⁵ and *Cryptosporidium* as a contributor to nosocomial infection is gaining increasing attention.^{25,46} Not surprisingly, there are data demonstrating nosocomial infections from *Cryptosporidium parvum*⁴⁷ as well as *Giardia intestinalis*.⁴⁸

Protozoa can contribute to nosocomial bacterial infections. Some protozoa can serve to protect bacteria from the biocidal effects of sanitation treatment methods.^{49,50} Protozoa, like those of the *Acanthamoeba* species, feed on bacteria. However, some bacteria can resist the digestive actions of their host and either destroy it or enjoy a symbiotic relationship providing it safe passage to an environment free of microbicidal activity. Organisms known to be involved in such mechanisms include ..."*Cryptococcus neoformans*, *Legionella* sp., *Chlamydomydia pneumoniae*, *Mycobacterium avium*, *Listeria monocytogenes*, *Pseudomonas aeruginosa*, and *Francisella tularensis*, and emerging pathogens, such as *Bosea* spp., *Simkania negevensis*, *Parachlamydia acanthamoebae*, and *Legionella*-like amoebal pathogens."⁴⁹

Therefore, a variety of microorganisms can be found in hospital water and are shown to have caused morbidity in patients. Some patients are at greater risk than others.

PATIENTS AT RISK

Patients who are immune compromised appear most susceptible to the risks of infectious complications

consequent to exposure to contaminated water sources, an observation that has been substantiated by a number of recent reviews.^{26,51-53} Included in the high-risk category are intensive care ward patients,^{15,54-58} neonates⁵⁹⁻⁶⁵ and patients with HIV and AIDS,⁶⁶⁻⁶⁹ cystic fibrosis,⁷⁰ those undergoing renal dialysis,⁷¹ transplantation,⁷²⁻⁷⁵ hematologic procedures,⁷⁶⁻⁸⁰ cancer therapy,⁸¹ and burn treatment.⁸²⁻⁸⁶

Immune status is not the only predictor of susceptibility to infectious complications as summarized in a model described by Duncan and Edberg⁸⁷ (Figure 3). Microbe virulence, dose of exposure and immunological status of the patient or target organ all contribute to the risk of disease development. Dose and/or virulence of microbial exposure may be a factor that contributes to certain water transmitted infectious complications documented subsequent to surgical,⁸⁸⁻⁹⁰ or moderately invasive diagnostic procedures such as endoscopy,^{13,32,91-93} laparoscopy⁹⁴ or colonoscopy,⁹⁵ where the patients are considered relatively immune competent. Alternatively, the gut manages a complex immune response to the myriad challenges presented to it and if altered by physical trauma or disease, infection can occur through this route.

It is important to appreciate the source of contaminated water reaching the patient. The sources of water-borne microbial contamination that have been identified as causative in transmitting disease are numerous and include hospital water,^{54,58,62,90} plumbing fixtures, faucets and sinks,⁶¹ bathtub,⁵⁹ showers and shower heads,^{11,96} humidifiers,⁸⁸ ice machines,⁹⁷⁻¹⁰¹ hydrotherapy equipment,^{83,86} pharmacy deionized water,¹⁰² tap water aerators,⁸¹ bath toys⁶⁴ and hemodialysis fluid.¹⁰³ All may derive, of course, from a common source of tap water.

RELATIVE RISK

The foregoing discussion illustrates the varied patient population in whom nosocomial infection derived from water-borne organisms present. Not all patients fall into the classification of those presumed or confirmed to be immune compromised. Moreover the notion of immune competency is more a function of the immune status of the target organ, number of microbes (classic dose-response relationship) and the virulence of the microorganism. This is particular true for water-borne organisms leading to gastritis and enteritis.⁸⁷

However, it is intuitively attractive to view generally immunocompromised patients as being at greater risk for any infection compared with those who are immune competent, and this has been well-detailed in a recent review.⁵³ The authors summarize the risk for infection based upon the level of immune compe-

$$\text{Infection} \propto \frac{[\text{Number of Microbes}] \times [\text{Virulence Characteristics}]}{\text{Immune Status of the Host}}$$

Fig 3. Relationship reflecting the risk of acquiring a nosocomial infection.⁸⁷

tency, infectious dose, virulence of the organism and predilection of the pathogen for a target organ or tissue. From a practical perspective, they emphasize their previously published¹⁰⁴ categorization of patients with different degrees of immune suppression and suggested corresponding levels of protection against contaminated drinking water. An adaptation of their schema is shown in Table 2, modified by including additional patient groups derived from the discussion above. These patients are suspected to be immunocompromised to some extent.

It is worth noting that we included transfusion recipients in the mildly immunocompromised group although consensus is lacking. However, the controversy over the clinical implications of the immunosuppressive effect of transfusion has been reviewed and there are ample data to support the view that transfusion recipients are immune compromised.^{105,106}

Preventing water-borne nosocomial infections can be approached by controlling that which is amenable to control. Immune competency of the patient may be out of reach during the course of treatment. Virulence of the microorganism is biologically determined and can be altered by changing the environmental conditions with the presence of antibiotics, pH altering agents and perhaps even iron chelators. The dose of microbes, however, is the easiest to address and should be the first target in preventing or minimizing water-borne nosocomial infections and we look to standards for guidance in how to accomplish this.

RISK MANAGEMENT WITH STANDARDS

Unfortunately, there are no international drinking water standards. The World Health Organization (WHO) publishes the Guidelines for Drinking Water Quality,¹⁰⁷ which many countries use as the basis to establish their own national standards for community water. Guidelines are what the name implies, recommendations that are without legal implication but "standards" have regulatory significance and are enforceable. The guidelines represent a scientific assessment of the risks to health from biological and chemical constituents of drinking water and of the effectiveness of relevant control and treatment measures.

Table 2. Characterization of patient populations at risk for infection from drinking water and corresponding risk-risk reduction behaviors

Immunosuppression level	Patient population	Risk reduction behavior
None	Minor surgical or diagnostic procedures (endoscopy, laparoscopy, colonoscopy)	No exposure of medical devices to tap water
1. Mild	Acute or chronic leukemia, malignant lymphoma, childhood histiocytosis X under maintenance without neutropenia Solid tumors (within 6 mo of chemotherapy) Long-term corticosteroid therapy with <20 mg/d prednisone or equivalent Autologous stem cell transplant (within 6 mo of discharge) Surgical patients. Blood component transfusion recipient Cystic fibrosis Renal dialysis	Avoid any circumstances with elevated infection risks (such as drinking water from uncontrolled sources)
2. Moderate	Acute or chronic leukemia, malignant lymphoma, childhood histiocytosis X solid tumors under intensive treatment (expected duration of neutropenia <500/ μ L for \leq 10 days) Long-term corticosteroid therapy with \geq 20 mg/d prednisone or equivalent Solid organ transplant after intensive treatment phase AIDS with a count of CD4+ cells less than 200 μ L Burns: Second-degree burns covering 15% to 20% of the body on an adult or covering over 10% to 20% of the body on a child	Drinking water should have an additional antimicrobial barrier to tap water Bathroom installations should be controlled for bacterial reservoirs
3. Severe	Acute or chronic leukemia, malignant lymphoma, childhood histiocytosis X solid tumors under intensive treatment (expected duration of neutropenia <500/ μ L for >10 days) Solid organ transplant under intensive treatment phase (induction or rejection therapy) Allogeneic stem cell transplant (first 6-12 mo after engraftment) AIDS with a count of CD4+ cells less than 200 μ L and an additional factor of immunosuppression (eg, neutropenia, corticosteroids) Second-degree burns covering more than 20% of the body. Third-degree burns covering more than 10% of the body Any fourth-degree burn. Neonates	Any water for human use should have a very low bacterial count (use water filters/controlled carbonated water) Strict control of bath installation and water for showering (showering to be avoided if no control possible)
4. Extreme	Allogeneic stem cell transplantation (until engraftment)	Only sterile fluids for drinking, mouth care, and washing allowed

Adapted from Glasmacher et al.⁵³ and Engelhart et al.¹⁰⁴

At the current time it is difficult to find a compilation of guidelines and regulations encompassing a global view of microbial contaminants in drinking water. The US FDA has enacted legislation that addresses this topic in an indirect way.¹⁰⁸ If total heterotrophic plate count (includes all bacteria) exceeds 500 CFU/mL then attention is directed toward the water treatment method. Coliforms must not be detected in more than 5% of samples processed with a minimum of 40

samples per month. Fewer than 40 per month reduces the limit of tolerance to no more than 1 coliform positive sample. It is suggested that the treatment be adjusted to result in levels of bacteria below this value. It is implied that *Cryptosporidium* and *Giardia* will be addressed if the treatment method is adequately adjusted.

There are minor differences throughout the global community but common to all is a focus on coliform

bacteria. Canada has established similar limits of <500 CFU/mL total heterotrophic plate counts and zero coliforms in a 100 mL sample.¹⁰⁹ The UK,¹¹⁰ Italy,¹¹¹ Germany,¹¹² Belgium,¹¹⁵ and New Zealand¹¹⁴ use the zero coliform in 100 mL sample rule with no attention afforded to other microorganisms.

RISK MANAGEMENT IN THE HOSPITAL

In hospital or health care settings, nosocomial infection is a concern, and hospital water may be a source of patient exposure. What is the approach to guidelines or standards for hospital water? Table 3 shows a contrast between the US Centers for Disease Control (CDC) guidelines, Germany's ordinance and France's guidelines where it addresses high-risk patients exposure to *Legionella* in hospital water. The Table shows the European community at least beginning to acknowledge, identify and make recommendations for high-risk patients within the hospital. There is heterogeneity with approaches for monitoring and reporting hospital-borne pathogens.

However, attesting to the increased concern over nosocomial infections, the Joint Commission on Accreditation of Healthcare Organization (JCAHO pronounced "jayco") is implementing a requirement to report hospital acquired infections (HAI) with a phase-in beginning January, 2005 before full enactment in July.¹¹⁵ These data will provide an opportunity to enhance our understanding of the magnitude of the contribution of contaminated hospital water to nosocomial infections. Water should be considered one unprotected source of exposure to be investigated. There are good reasons why hospital water has been above suspicion as a source of nosocomial infections.

CONTAMINATION CAN BE UNDERESTIMATED

Although most guidelines and standards feature coliforms as the foremost marker of microbial water quality, there are clearly opportunities for contamination to be missed and this can lead to clinical morbidity. These opportunities are availed through:

- plumbing and water flow considerations with the elaboration of a microbial-derived microenvironment of self-protection in the form of "biofilm" and,
- underestimates of the true bioburden associated with variations in test methodologies intended to quantify the microbial bioburden.

BIOFILM

In aqueous environments, microorganisms preferentially colonize surfaces to increase their chances of survival.¹¹⁶ To aid their adhesion to surfaces, copious

amounts of sticky extracellular polysaccharides (EPS) are produced which ultimately envelop the cells. Water channels or void spaces of variable size are dispersed throughout the EPS and microbial cell complex, allowing nutrients to diffuse in, and waste products from cell metabolism to be removed out of the gel-like network.¹¹⁷ A biofilm may therefore be defined as "an organized community of both viable and non-viable microorganisms, EPS, absorbed nutrients and entrained particles adherent to an inert or living surface."¹¹⁸ Microbial cells account for only a small percentage of the volume in biofilms (5-25%), with the polymer network (which contains 70-90% water) occupying the remaining volume.¹¹⁹⁻¹²¹ Although many different microbial species can form biofilms, the mechanisms involved in biofilm formation are generally similar in each case.^{122,123} This process is summarized for water-borne bacteria colonizing any environmental surface and further explained with the assistance of Figure 4.

Briefly, surfaces are rendered attractive to microbes with a pre-conditioning coat such as protein.¹²⁴ Bacteria are transported to a pre-conditioned surface by a combination of Brownian motion, frictional drag, electrostatic attraction, gravitational forces and turbulent "downsweeps."^{125,126} The cells reversibly attach to the surface, followed by an irreversible stage when EPS is produced in large quantities. Cell proliferation occurs, resulting in a monolayer of cells which ultimately results in the formation of microcolonies within an EPS matrix i.e., a biofilm. A typical example of biofilm is shown in Figure 5 in contrast with similar surface not exposed to bacteria.

Cell growth in the biofilm continues until a critical size is reached. Recently, the importance of intercellular communication between bacterial cells, a phenomenon also known as quorum sensing on biofilm formation has been realized.¹²⁷⁻¹³⁰ During the initial stages of biofilm formation, bacterial cells adsorb to the surface and release signals, known as autoinducers, into the surrounding environment. Autoinducers attract other bacteria to the surface, and induce cell division of adsorbed cells. The intracellular communication continues until the population reaches a threshold level at which the biofilm can be sustained.¹³¹

Further surface colonization may occur if sections of biofilm are forcibly removed by shear forces operating on the biofilm (erosion or sloughing), or by the controlled release of single, daughter cells from the outer perimeter of the biofilm. Although not fully understood, the latter is believed to be genetically controlled,¹³² and as such, cannot be easily controlled by existing water quality maintenance programs. Other factors can contribute to biofilm formation and are summarized in Table 4. This means that any area of the

Table 3. Global potable water quality guidelines and standards

	USA-CDC guidelines ²¹	Germany ordinance ¹⁸³ (operative as of January 2003)	France guidelines ¹⁸⁴
Identified organisms concerned	<i>Legionella</i> species	Addresses proliferation of pathogens as: <i>Legionella</i> species, <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter</i> , and others that are bound to biofilms	<i>Legionella pneumophila</i>
Environmental surveillance	No recommendation can be made about routinely culturing water systems in health care facilities that do not have patient care areas (eg, transplant units) for persons at high risk for <i>Legionella</i> infection Periodic culturing for Legionellae in water samples from the transplant unit(s).	Local public health authorities play role in inspection, supervision of water installations, surveillance, and risk assessments Addresses all hospital departments	Routine sampling in hospital area for high-risk patients (immune compromised, transplant, NICU, corticotherapy patients) to assure that <i>L pneumophila</i> concentration is below level of detection. Sampling points and size recommended
Routine treatment for water quality	Where practical, maintain potable water at the outlet at >51°C (>124°F) or <20°C (<68°F), especially in facilities housing organ transplants or other patients at high risk	Recognizes biofilms and that they are less affected by disinfectants Compared with pathogens within house plumbing, systems are not allowed at levels that have adverse effects on human health, eg, concentrations <1 CFU/mL ¹¹²	Create safe points of use for water for high-risk patients where specific water treatment methods are employed The aim of preventative actions is to eliminate conditions favorable to the survival and proliferation of <i>Legionella</i> and limit their distribution in aerosol form. Point of interest is not only the tap but showers and hand sprays.
Disinfection-specific after outbreak	If heated water system is implicated, decontaminate by superheating (71°C-77°C) flushing system minimum of 5 minutes or by hyperchlorination	Changing the prevention strategies and indicate that point-of-use filters on water taps and fittings in intensive care units have led to a distinct reduction of rate of infections Advantage of filtration is also cost cutting potential of antibiotic use For high-risk areas of hematology-oncology wards and intensive care units, point-of use filter systems are now recommended	Treatment option is 0.2-µm filtration. Continuous use of disinfectants in hot water is to be avoided
Reporting requirements	Contact the local or state health department or CDC if the disease is reportable in the state or if assistance is needed	Every irregularity detected must be reported to the local public health authority	Requirements to report to public health authority and National Reference for <i>Legionella</i>

water distribution both leading to and within the hospital environment may be subject to biofilm formation as indicated in Figure 6 and further explained in the legend.

RESISTANCE OF BIOFILMS

Surface-associated microorganisms greatly outnumber planktonic cells, and research has shown that biofilm bacteria (sessile bacteria) are profoundly different from planktonic cells (free-living bacteria), and

demonstrate some unique characteristics not observed if the cells are returned to the planktonic state.^{125,132-135}

It has been widely reported that biofilm bacteria have an increased resistance to antimicrobial agents, compared to their planktonic counterparts. The application of increasingly sophisticated technologies for studying biofilms, including confocal scanning laser microscopy (CSLM) and molecular fluorescent probes have helped to elucidate some potential factors involved in this resistance. However, it seems likely that a combination of factors contributes to this phenomenon:




Fig 4. Biofilm formation adapted from several references.^{122,126,204-207}

- The antimicrobial agents may fail to penetrate through the thick EPS, the dense cell aggregates and microcolonies, or bind to the polymeric matrix before they reached the target cells.^{116,136,137}
- The chemicals may not be effective over the range of cell growth rates and microenvironments distributed through the biofilm (e.g. facultative anaerobes growing in center of biofilm).¹³⁸⁻¹⁴¹
- Resistance of bacterial cells may be increased by genetic transfer within cells in close proximity in the biofilm.^{142,143}

REMOVAL OF BIOFILM

Adequate management of hospital water systems is a key factor in microbial control, and various physical and chemical approaches are employed (Table 4). Chlorination is undoubtedly the most commonly used treatment, though it has been demonstrated that monochloramine is more effective on biofilms.^{144,145} Other chemical treatments include the application of silver or copper ions, which have been shown to be effective against *L. pneumophila*.¹⁴⁶ Ozonation may also be considered for microbial control in water systems, though the short half-life, potential incom-

plete penetration of biofilm and cost associated with treatment makes this a less commonly employed mechanism.

Physical treatments include the application of heat, ultraviolet irradiation and filtration. The use of heat must be carefully considered, as research has shown that water held in a storage tank at 30-54°C may induce the proliferation of *L. pneumophila* and thermophilic non-tuberculosis *Mycobacterium* (NTM) *sp.*, both of which are capable of growth in temperatures up to 45°C.^{25,147} There is also evidence that bacteria may become resistant to UV irradiation at 254 nm (the wavelength used for microbial control), and that exposure time may be inadequate to ensure all micro-organisms present in the water are treated.¹⁴⁸⁻¹⁵¹

QUANTIFICATION OF WATER-BORNE BACTERIA

In the face of voluminous medical literature it is difficult to envision how hospital water contamination has escaped attention as an important source of microbial exposure to patients. Biofilm has likely played an important role in perpetuating the mystery and so too have methods of testing for water-borne organisms.




Fig 5. Electronmicrograph of 0.2- μm nylon (Posidyne) filter media subjected to sterile saline (panel A) vs. *P. aeruginosa* suspension (1×10^5 CFU/mL (panel B) for 1 hour daily for 7 consecutive days at low flow (10 mL/min).

It should be appreciated that water-borne organisms grow in nutrient-poor environments and have to adapt to nutrient-rich physiologic fluids. While most hospitals routinely sample their water sources for bioburden content, the methods employed vary considerably, and may lead to potential underestimation of the true extent of contamination. It is imperative to realize that bacteria residing in water are fundamentally different than those surviving in a nutrient-rich environment.^{152,153} Due to the low nutrient content of drinking water, bacteria surviving in such environments, referred to as oligotrophic bacteria,¹⁵⁴ have evolved several ways to survive, including a broad substrate range, growth at low nutrient levels (1-15 mg carbon/L), lower metabolism rates, a decrease in cell size, and increased cell surface area and adhesion to surfaces.^{153,155-158} The methods used to quantify

Table 4. Some factors affecting biofilm formation in water systems

Factor	Influence on biofilms	Reference numbers
Water chemistry	Multivalent cations (Ca^{2+} , Mg^{2+}) stabilize EPS network Assimilable organic carbon (AOC) levels $>50 \mu\text{g/L}$ may be conducive to microbial growth	185-187
Flow	Influences biofilm structure Laminar flow forms circular microcolonies Turbulent flow forms filamentous-like microcolonies	188
Water stagnation	Dead-legs, heat exchangers, and holding tanks create suitable environment for bacterial colonization and proliferation	150, 171, 189
Piping materials	Smoother, inert surface in piping minimizes biofilm formation and allows improved contact with disinfectants	190
Piping corrosion	Efficiency of chlorination on biofilm removal lowered Production of corrosion products (eg, phosphates, carbonates) may provide nutrients to biofilm	191
High shear stress	Increased resistance to detachment but increased time required for cell attachment	192
Regular flushing of piping	Increased removal of planktonic organisms	187

water-borne organisms should involve the use of nutrient-poor growth media, such as R2A. Whereas, attempt to grow water-borne organisms in nutrient-rich media, such as heterotrophic plate count agar (HPCA), will underestimate the bioburden.

Therefore, when using plate culture methods to determine the bacterial content of water, use of a dilute growth medium such as R2A media¹⁵⁹ is generally favored, and significantly higher bacterial recoveries have been reported with dilute medium as compared with recovery on high nutrient growth media e.g. HPCA.^{154,159-161} Similarly, plates should be incubated at 25-30°C for a minimum of 7 days to maximize bacterial recovery.^{159,160,162-164} To emphasize the point, we have undertaken a comparison of HPCA and R2A media by inoculating plates with each of the two media using an aliquot of the same water sample and incubated the plates at 25°C for up to 15 days. The




Fig 6. Pictorial representation of the mechanisms by which contaminated hospital water may contribute to nosocomial infections (adapted from Anaissie et al⁶). Flow diagram depicting the accumulation of biofilm from water treatment facility to its point-of-use in the hospital. Large pipes bear high flows at a location very close to the source of treatments to limit the bioburden of microorganisms. As the distribution of water is divided into smaller and smaller pipes with more variable flow with changing patterns of use, biofilm can elaborate to considerably greater extents. At the point-of-use, biofilm can serve as a repository for the continual presentation of viable microbes to patients, care givers, and environmental surfaces with which water may come in contact.

data, shown in Figure 7, illustrate the growth of microbes in R2A far exceed levels obtained from HPCA.

Other methods are available for bacterial detection, including ATP quantification,¹⁶⁵ epifluorescence microscopy,¹⁶⁶ and molecular based methods, such as polymerase chain reaction (PCR) gene probes^{151,167} and 16S rRNA sequencing.¹⁶⁸ However, these methods tend to be more costly, require specialized equipment, and trained operators to ensure correct sample preparation and data interpretation.

There are now sufficient data to support the view that pathogens contaminate hospital water, biofilm compromises the efficacy of common treatment

methods, standards are not optimal and testing may underestimate the true level of contamination. A simple solution to minimize the bioburden presented to patients may be a physical barrier in the form of point-of-use filtration for faucets and shower heads.

THE SIMPLICITY OF FILTRATION

Although 0.45 micron (μm) filtration was the standard filter grade designed to prevent the passage of bacteria, it is generally accepted that 0.2 μm filters represent a more effective barrier to bacteria transmission.¹⁶⁹ Although rare, there are conditions under




Fig 7. Effect of media composition on growth and quantification of waterborne bacteria from tap water samples. Tap water samples ($n=3$) were recovered from a domicile in a relatively affluent suburban community just outside of metropolitan New York. Equal volume aliquots were serially diluted in distilled deionized water and 100 μL were plated onto R2A or HPCA, incubated at 25°C and counted following days of incubation indicated.

which water-borne microbes can be recovered in the filtrate of such sized filters and some have argued 0.1 μm confers more absolute performance.¹⁷⁰ The CDC [United States Centers for Disease Control] has identified, as an alternative to sterile water, 0.2 μm filtered water to meet the standard of the highest quality of water that is practical for final rinse of endoscopes and other medical devices.^{21,171}

In the context of hospital water filtration, 0.2 μm filters are being used with success. In a pediatric nephrology unit with a case of Legionellosis, a look back investigation revealed 5 cases. *Legionella pneumophila* serotype 6 was identified in hospital water limited to the unit and clinicians elected to implement point-of-use water filtration as part of their infection control strategy since the outbreak was restricted to their unit and the installation and maintenance of filters were cost permissive.¹¹

At the 9th European Congress of Clinical Microbiology and Infectious Diseases held in Berlin in March, 1999, Hummel and co-workers,¹⁷² used point-of-use water filters. Filters were employed as part of an infection control strategy to minimize exposure to *Legionella* serogroup 1 in a heart transplant unit.

Legionella had been refractory to conventional sanitation treatments. The incidence of *Legionella* infection confirmed by urine antigen testing approximated 23% before point-of use water filters were installed. After filter installation, as part of the infection control strategy, the rate dropped to 15% and it was further reduced to 1.9% with urine *Legionella* antigen screening and the corresponding use of antibiotics.

Application of sterile filters on faucets and shower-heads became part of an infection control program in response to an outbreak of 6 cases of *P. aeruginosa* (2 pneumonias, 2 septicemias and 2 wound infections) in an adult hematology/oncology unit at the University of Bonn in Germany.¹⁷³ A survey of 209 environmental samples revealed contamination in surface cleaning equipment, taps, wash basin drains and showers. After implementation of the strategy involving point-of use water filters, the rate of hospital acquired infection reverted to pre-outbreak levels.

Vonberg and co-workers of the Medical School Hannover (Germany) evaluated the performance of 0.2 μm point-of-use tap water filters in 3 intensive care units involving 785 samples.¹⁷⁴ Without filtration, it was shown that over 90% of 32 samples collected were positive for *Legionella* at concentrations ranging from 1–106 CFU/mL. In contrast, 251 samples recovered from taps fitted with filters for 7 days failed to recover any *Legionella* in 250 samples and in the one, the residual concentration was 1 CFU/mL. Despite claims to the contrary, not all filters are alike¹⁷⁵ and confidence in their use should be based upon performance claims and actual clinical use experience.

CONCLUSION

The inadequacy of water treatment standards is being recognized.¹⁷⁶ A greater appreciation is developing for the dangers of water-borne microorganism that survive within, and are released from, the protection of biofilm.¹⁷⁷⁻¹⁷⁹ Drug therapies are being developed to target biofilm.¹⁸⁰⁻¹⁸² Increasing recognition of the role that *Acanthamoeba*, a common water-borne protozoan, plays in protecting bacteria from sanitation methods and increasing the likelihood of passing on the more virulent strains of pathogens contributes to the mounting concern.

Most importantly, the value of microbial protection barriers afforded by 0.2 μm filtration at the point-of-use is gaining momentum with studies such as that by Trautmann and co-workers, in this issue of *FILTRATION*, illustrating the benefit of its use. More aggressive filtration strategies are available to serve as a barrier to viral particles and, with increasing characterization of the magnitude of their effect, such technologies are available and can be implemented easily.

Table 5. Comparison of water treatment methods for the reduction of microbial contamination

Method	Ease of installation	Cost	Maintenance	Efficacy		Disadvantage	Reference numbers
				Short-term	Long-term		
Heat	Easy	Low	Easy	Good	Poor	Failure to maintain consistent temperature Recolonization at low temperature Hard to reach all taps with dead-leg piping and antiscald valves Scalding potential Labor intensive Recontamination occurs in 30-60 days Increase in biofilm sloughing possible	76, 171, 191, 193
Chlorine	Difficult must hold 10-50 ppm for 12-24 hr, shock method or 1-2 ppm continuous	High	Fair-difficult	Good	Fair	Amoeba, harbingers of bacteria, are resistant to chlorine Recolonization after system disinfection <i>Legionella</i> species more resistant to chlorination System corrosion causes pipe leaks and can promote biofilm formation Carcinogenic byproducts (trihalomethanes) Chlorine levels checked frequently Potential resistance of Mycobacteria Does not penetrate into center of established biofilms	25, 76, 166, 171, 194-196
Chlorine dioxide	Fair	Low-Moderate	Fair-Difficult	Good	Poor	Unknown corrosive properties Unknown maintenance of effective concentration in hot water systems Does not penetrate completely into biofilm Costly	193, 197, 198
Monochloramines	Fair	Moderate	Fair-difficult	Good	N/A	More difficult to remove from water than chlorine or chlorine dioxide May not penetrate into biofilm Potential resistance of Mycobacteria Must be removed from water used for dialysis	199-201
Copper-silver ionization	Fair	Low-Moderate	Moderate			Metallic ions added to drinking water Works well only on water with low dissolved solids content Can corrode steel or galvanized pipe Not equally effective for all pathogens	202
UV	Fair, local effect	Moderate	Moderate cleaning for effective energy transmission	Good	Fair	Scale problems Electricians required Poor penetrating power of UV light in established biofilms	148, 149, 151

Table 5. (continued)

Method	Ease of installation	Cost	Maintenance	Efficacy		Disadvantage	Reference numbers
				Short-term	Long-term		
Ozone	Difficult	High	Moderate	Good	Poor	May cause injured cells Partially degraded organics may enhance biofilm formation Disinfects only at the point of injection Decomposes quickly in hot water Hard to hold effective concentration Specialized equipment required to generate ozone	193
POU filtration	Easy, immediate barrier	Low	Simple	Good	Good	Correct installation essential for bacterial removal	203

References

- Weinstein RA. Nosocomial infection update. *Emerg Infect Dis* 1998 Jul-Sep;4(3):416-20.
- Strausbaugh LJ. Nosocomial respiratory infections. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000. p. 3020-8.
- Roberts RR, Scott RD 2nd, Cordell R, Solomon SL, Steele L, Kampe LM, Trick WE, Weinstein RA. The use of economic modeling to determine the hospital costs associated with nosocomial infections. *Clin Infect Dis* 2003 Jun 1;36(11):1424-32.
- Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA* 2003 Oct 8;290(14):1868-74.
- Wilcox MH. Health-care-associated infection: morbidity, mortality and costs. *Hosp Med* 2004 Feb;65(2):88-91.
- Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. *Arch Intern Med* 2002 Jul 8;162(13):1483-92.
- Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. *Clin Microbiol Rev* 2002 Jul;15(3):506-26.
- Roig J, Sabria M, Pedro-Botet ML. Legionella spp.: community acquired and nosocomial infections. *Curr Opin Infect Dis* 2003 Apr;16(2):145-51.
- Stout JE, Yu VL. Hospital-acquired Legionnaires' disease: new developments. *Curr Opin Infect Dis* 2003 Aug;16(4):337-41.
- Sabria M, Campins M. Legionnaires' disease: update on epidemiology and management options. *Am J Respir Med* 2003;2(3):235-43.
- Campins M, Ferrer A, Callis L, Pelaz C, Cortes PJ, Pinart N, Vaque J. Nosocomial Legionnaire's disease in a children's hospital. *Pediatr Infect Dis J* 2000 Mar;19(3):228-34.
- Torii K, Iinuma Y, Ichikawa M, Kato K, Koide M, Baba H, Suzuki R, Ohta M. A case of nosocomial Legionella pneumophila pneumonia. *Jpn J Infect Dis* 2003 Jun;56(3):101-2.
- Levy PY, Teyssiere N, Etienne J, Raoult D. A nosocomial outbreak of Legionella pneumophila caused by contaminated transesophageal echocardiography probes. *Infect Control Hosp Epidemiol* 2003 Aug;24(8):619-22.
- Sabria M, Yu VL. Hospital-acquired legionellosis: solutions for a preventable infection. *Lancet Infect Dis* 2002 Jun;2(6):368-73.
- Kusnetsov J, Torvinen E, Perola O, Nousiainen T, Katila ML. Colonization of hospital water systems by legionellae, mycobacteria and other heterotrophic bacteria potentially hazardous to risk group patients. *APMIS* 2003 May;111(5):546-56.
- Yu VL. Resolving the controversy on environmental cultures for Legionella: a modest proposal. *Infect Control Hosp Epidemiol* 1998 Dec;19(12):893-7.
- Perola O, Kauppinen J, Kusnetsov J, Heikkinen J, Jokinen C, Katila ML. Nosocomial Legionella pneumophila serogroup 5 outbreak associated with persistent colonization of a hospital water system. *APMIS* 2002 Dec;110(12):863-8.
- Patterson WJ, Hay J, Seal DV, McLuckie JC. Colonization of transplant unit water supplies with Legionella and protozoa: precautions required to reduce the risk of legionellosis. *J Hosp Infect* 1997 Sep;37(1):7-17.
- Legnani PP, Leoni E, Corradini N. Legionella contamination of hospital water supplies: monitoring of private healthcare facilities in Bologna, Italy. *J Hosp Infect* 2002 Mar;50(3):220-3.
- Marrie TJ, Haldane D, Bezanson G, Peppard R. Each water outlet is a unique ecological niche for Legionella pneumophila. *Epidemiol Infect* 1992 Apr;108(2):261-70.
- Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R, CDC, Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. *MMWR Recomm Rep* 2004 Mar 26;53(RR-3):1-36.
- Keane T. Water watch. A look at water quality recommendations + requirements. *Health Facil Manage* 2004 Jan;17(1):20-2.
- Rautelin H, Koota K, von Essen R, Jahkola M, Siitonen A, Kosunen TU. Waterborne Campylobacter jejuni epidemic in a Finnish hospital for rheumatic diseases. *Scand J Infect Dis* 1990;22(3):321-6.
- Picard B, Goulet P. Seasonal prevalence of nosocomial Aeromonas hydrophila infection related to aeromonas in hospital water. *J Hosp Infect* 1987 Sep;10(2):152-5.
- Squier C, Yu VL, Stout JE. Waterborne Nosocomial Infections. *Curr Infect Dis Rep* 2000 Dec;2(6):490-6.
- Merlani GM, Francioli P. Established and emerging waterborne nosocomial infections. *Curr Opin Infect Dis* 2003 Aug;16(4):343-7.
- El Sahly HM, Septimus E, Soini H, Septimus J, Wallace RJ, Pan X, Williams-Bouyer N, Musser JM, Graviss EA. Mycobacterium smitiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. *Clin Infect Dis* 2002 Oct 1;35(7):802-7.
- Chang CT, Wang LY, Liao CY, Huang SP. Identification of non-tuberculous mycobacteria existing in tap water by PCR-restriction fragment length polymorphism. *Appl Environ Microbiol* 2002 Jun;68(6):3159-61.

29. Vanholder R, Vanhaecke E, Ringoir S. Waterborne Pseudomonas septicemia. *ASAIO Trans* 1990 Jul-Sep;36(3):M215-6.
30. Stamm-Balderjahn S, Zuschneid I, Hansen S, Nitzschke-Tiemann, Behnke M, Ruden H, Gastmeier P. Analysis of outbreaks with *P. aeruginosa* described in the literature. *Poster abstract presented at the Fourteenth Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA)*; April 19, 2004; Philadelphia, PA (Abstract #292).
31. Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. *Infect Control Hosp Epidemiol* 2004 Mar;25(3):231-9.
32. Muscarella LE. Contribution of tap water and environmental surfaces to nosocomial transmission of antibiotic-resistant Pseudomonas aeruginosa. *Infect Control Hosp Epidemiol* 2004 Apr;25(4):342-5.
33. Arvanitidou M, Kanellou K, Constantinides TC, Katsouyannopoulos V. The occurrence of fungi in hospital and community potable waters. *Lett Appl Microbiol* 1999 Aug;29(2):81-4.
34. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. *Clin Infect Dis* 2001 Nov 1;33(9):1546-8.
35. Warris A, Voss A, Abrahamsen TG, Verweij PE. Contamination of hospital water with Aspergillus fumigatus and other molds. *Clin Infect Dis* 2002 Apr 15;34(8):1159-60.
36. VandenBergh MF, Verweij PE, Voss A. Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. *Diagn Microbiol Infect Dis* 1999 Jul;34(3):221-7.
37. Warris A, Klaassen CH, Meis JF, De Ruiter MT, De Valk HA, Abrahamsen TG, Gaustad P, Verweij PE. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. *J Clin Microbiol* 2003 Sep;41(9):4101-6.
38. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, Monson TP, Walsh TJ. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. *Blood* 2003 Apr 1;101(7):2542-6.
39. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Mahfouz TH, Rex JH, Summerbell RC, Walsh TJ. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. *Clin Infect Dis* 2002 Oct 15;35(8):E86-8.
40. Pond K. (ed) In: Emerging issues in water and infectious disease. World Health Organization 2003 (ISSN 1728-2160) Retrieved online at http://www.who.int/water_sanitation_health/emerging/en/emerging.pdf on May 17, 2004.
41. Schvoerer E, Bonnet F, Dubois V, Rogues AM, Gachie JP, Lafon ME, Fleury HJ. A hospital outbreak of gastroenteritis possibly related to the contamination of tap water by a small round structured virus. *J Hosp Infect* 1999 Oct;43(2):149-54.
42. Khanna N, Goldenberger D, Graber P, Battegay M, Widmer AF. Gastroenteritis outbreak with norovirus in a Swiss university hospital with a newly identified virus strain. *J Hosp Infect* 2003 Oct;55(2):131-6.
43. Morris RD, Naumova EN, Griffiths JK. Did Milwaukee experience waterborne cryptosporidiosis before the large documented outbreak in 1993? *Epidemiology* 1998 May;9(3):264-70.
44. Naumova EN, Egorov AI, Morris RD, Griffiths JK. The elderly and waterborne Cryptosporidium infection: gastroenteritis hospitalizations before and during the 1993 Milwaukee outbreak. *Emerg Infect Dis* 2003 Apr;9(4):418-25.
45. Leclerc H, Schwartzbrod L, Dei-Cas E. Microbial agents associated with waterborne diseases. *Crit Rev Microbiol* 2002;28(4):371-409.
46. Weber DJ, Rutala WA. The emerging nosocomial pathogens Cryptosporidium, Escherichia coli O157:H7, Helicobacter pylori, and hepatitis C: epidemiology, environmental survival, efficacy of disinfection, and control measures. *Infect Control Hosp Epidemiol* 2001 May;22(5):306-15.
47. el-Sibaei MM, Rifaat MM, Hameed DM, el-Din HM. Nosocomial sources of cryptosporidial infection in newly admitted patients in Ain Shams University Pediatric Hospital. *J Egypt Soc Parasitol* 2003 Apr;33(1):177-88.
48. Gusmao RH, Mascarenhas JD, Gabbay YB, Lins-Lainson Z, Ramos FL, Monteiro TA, Valente SA, Linhares AC. Rotaviruses as a cause of nosocomial, infantile diarrhea in northern Brazil: pilot study. *Mem Inst Oswaldo Cruz* 1995 Nov-Dec;90(6):743-9.
49. Greub G, Raoult D. Microorganisms resistant to free-living amoebae. *Clin Microbiol Rev* 2004 Apr;17(2):413-33.
50. Nwachuku N, Gerba CP. Health effects of Acanthamoeba spp. and its potential for waterborne transmission. *Rev Environ Contam Toxicol* 2004;180:93-131.
51. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. *Annu Rev Microbiol* 1998;52:453-90.
52. Emmerson AM. Emerging waterborne infections in health-care settings. *Emerg Infect Dis* 2001 Mar-Apr;7(2):272-6.
53. Glasmacher A, Engelhart S, Exner M. Infections from HPC [heterotrophic plate count] organisms in drinking-water amongst the immunocompromised. In: Bartram J, Cotruvo J, Exner M, Fricker C, Glasmacher A, editors. *Heterotrophic Plate Counts and Drinking-water Safety*. London, UK: World Health Organization; IWA Publishing; 2003. p. 137-45.
54. Wang SH, Sheng WH, Chang YY, Wang LH, Lin HC, Chen ML, Pan HJ, Ko WJ, Chang SC, Lin FY. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. *J Hosp Infect* 2003 Feb;53(2):97-102.
55. Trautmann M, Michalsky T, Wiedeck H, Radosavljevic V, Ruhnke M. Tap water colonization with Pseudomonas aeruginosa in a surgical intensive care unit (ICU) and relation to Pseudomonas infections of ICU patients. *Infect Control Hosp Epidemiol* 2001 Jan;22(1):49-52.
56. Bukholm G, Tannaes T, Kjelsberg AB, Smith-Erichsen N. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. *Infect Control Hosp Epidemiol* 2002 Aug;23(8):441-6.
57. Debast SB, Meis JF, Melchers WJ, Hoogkamp-Korstanje JA, Voss A. Use of interrepeat PCR fingerprinting to investigate an Acinetobacter baumannii outbreak in an intensive care unit. *Scand J Infect Dis* 1996;28(6):577-81.
58. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. *J Hosp Infect* 1998 May;39(1):53-62.
59. Vochem M, Vogt M, Doring G. Contaminated tub bath of neonate: Sepsis in a newborn due to Pseudomonas aeruginosa from a contaminated tub bath. *N Engl J Med*. 2001;2345(5):378-9.
60. Jeong SH, Kim WM, Chang CL, Kim JM, Lee K, Chong Y, Hwang HY, Baek YW, Chung HK, Woo IG, Ku JY. Neonatal intensive care unit outbreak caused by a strain of Klebsiella oxytoca resistant to aztreonam due to overproduction of chromosomal beta-lactamase. *Hosp Infect* 2001 Aug;48(4):281-8.
61. Su LH, Wu TL, Chiu YP, Chia JH, Kuo AJ, Sun CF, Lin TY, Leu HS. Klebsiella pneumoniae from contaminated sinks in NICU. Outbreaks of nosocomial bloodstream infections associated with multiresistant Klebsiella pneumoniae in a pediatric intensive care unit. *Infection Control Group. Chang Gung Med J* 2001 Feb;24(2):103-13.
62. Hoque SN, Graham J, Kaufmann ME, Tabaqchali S. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. *J Hosp Infect* 2001 Mar;47(3):188-92.
63. Verweij PE, Meis JF, Christmann V, Van der Bor M, Melchers WJ, Hilderink BG, Voss A. Nosocomial outbreak of colonization and

- infection with *Stenotrophomonas maltophilia* in preterm infants associated with contaminated tap water. *Epidemiol Infect* 1998 Jun; 120(3):251-6.
64. Buttery JP, Alabaster SJ, Heine RG, Scott SM, Crutchfield RA, Bigham A, Tabrizi SN, Garland SM. Multiresistant *Pseudomonas aeruginosa* outbreak in a pediatric oncology ward related to bath toys. *Pediatr Infect Dis J* 1998 Jun; 17(6):509-13.
 65. Grundmann H, Kropec A, Hartung D, Berner R, Daschner F. *Pseudomonas aeruginosa* in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen. *J Infect Dis* 1993 Oct; 168(4):943-7.
 66. Blatt SP, Dolan MJ, Hendrix CW, Melcher GP. Legionnaires' disease in human immunodeficiency virus-infected patients: eight cases and review. *Clin Infect Dis* 1994 Feb; 18(2):227-32.
 67. Ravn P, Lundgren JD, Kjaeldgaard P, Holten-Anderson W, Hojlyng N, Nielsen JO, Gaub J. Nosocomial outbreak of cryptosporidiosis in AIDS patients. *BMJ* 1991 Feb 2; 302(6771):277-80.
 68. Kolmos HJ, Lerche A, Kristoffersen K, Rosdahl VT. Pseudo-outbreak of *Pseudomonas aeruginosa* in HIV-infected patients undergoing fiberoptic bronchoscopy. *Scand J Infect Dis* 1994; 26(6):653-7.
 69. Hillebrand-Haverkort ME, Kolk AH, Kox LF, Ten Velden JJ, Ten Veen JH. Generalized mycobacterium genavense infection in HIV-infected patients: detection of the mycobacterium in hospital tap water. *Scand J Infect Dis* 1999; 31(1):63-8.
 70. Bosshammer J, Fiedler B, Gudowius P, von der Hardt H, Romling U, Tummler B. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period. *J Hosp Infect* 1995 Dec; 31(4):261-74.
 71. Chertow GM. Dialysis *Ochrobactrum anthropi* bacteremia in a patient on hemodialysis. *Am J Kidney Dis* 2000 Jun; 35(6):E30.
 72. Levin AS, Caiiffa Filho HH, Sinto SI, Sabbaga E, Barone AA, Mendes CM. An outbreak of nosocomial Legionnaires' disease in a renal transplant unit in Sao Paulo, Brazil. Legionellosis Study Team. *J Hosp Infect* 1991 Jul; 18(3):243-8.
 73. Bangsberg JM, Uldum S, Jensen JS, Bruun BG. Nosocomial legionellosis in three heart-lung transplant patients: case reports and environmental observations. *Eur J Clin Microbiol Infect Dis* 1995 Feb; 14(2):99-104.
 74. Le Saux NM, Sekla L, McLeod J, Parker S, Rush D, Jeffery JR, Brunham RC. Epidemic of nosocomial Legionnaires' disease in renal transplant recipients: a case-control and environmental study. *CMAJ* 1989 May 1; 140(9):1047-53.
 75. Kallings I, Kallings LO. Epidemiological patterns in legionellosis in Sweden. *Zentralbl Bakteriol Mikrobiol Hyg [A]* 1983 Jul; 255(1):71-5.
 76. Oren I, Zuckerman T, Avivi I, Finkelstein R, Yigla M, Rowe JM. Nosocomial outbreak of *Legionella pneumophila* serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control. *Bone Marrow Transplant* 2002 Aug; 30(3): 175-9.
 77. Grigis A, Goglio A, Parea M, Gnechi F, Minetti B, Barbui T. Nosocomial outbreak of severe *Pseudomonas aeruginosa* infections in haematological patients. *Eur J Epidemiol* 1993 Jul; 9(4):390-5.
 78. Gilchrist MJ, Kraft JA, Hammond JG, Connelly BL, Myers MG. Detection of *Pseudomonas mesophilica* as a source of nosocomial infections in a bone marrow transplant unit. *J Clin Microbiol* 1986 Jun; 23(6):1052-5.
 79. Perola O, Nousiainen T, Suomalainen S, Aukee S, Karkkainen UM, Kauppinen J, Ojanen T, Katila ML. Recurrent *Sphingomonas paucimobilis* -bacteraemia associated with a multi-bacterial water-borne epidemic among neutropenic patients. *J Hosp Infect* 2002 Mar; 50(3):196-201.
 80. Alberti C, Bouakline A, Ribaud P, Lacroix C, Rousselot P, Leblanc T, Derouin F, Aspergillus Study Group. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. *J Hosp Infect* 2001 Jul; 48(3):198-206.
 81. Kappstein I, Grundmann H, Hauer T, Niemeyer C. Aerators as a reservoir of *Acinetobacter junii*: an outbreak of bacteraemia in paediatric oncology patients. *J Hosp Infect* 2000 Jan; 44(1):27-30.
 82. Kolmos HJ, Thuesen B, Nielsen SV, Lohmann M, Kristoffersen K, Rosdahl VT. Outbreak of infection in a burns unit due to *Pseudomonas aeruginosa* originating from contaminated tubing used for irrigation of patients. *J Hosp Infect* 1993 May; 24(1):11-21.
 83. Embil JM, McLeod JA, Al-Barrak AM, Thompson GM, Aoki FY, Witwicki EJ, Stranc MF, Kabani AM, Nicoll DR, Nicolle LE. An outbreak of methicillin resistant *Staphylococcus aureus* on a burn unit: potential role of contaminated hydrotherapy equipment. *Burns* 2001 Nov; 27(7):681-8.
 84. Turner AG, Higgins MM, Craddock JG. Disinfection of immersion tanks (Hubbard) in a hospital burn unit. *Arch Environ Health* 1974 Feb; 28(2):101-4.
 85. Podnos YD, Cinat ME, Wilson SE, Cooke J, Gornick W, Thrupp LD. Eradication of multi-drug resistant *Acinetobacter* from an intensive care unit. *Surg Infect (Larchmt)* 2001 Winter; 2(4):297-301.
 86. Tredget EE, Shankowsky HA, Joffe AM, Inkson TI, Volpel K, Paranchych W, Kibsey PC, Alton JD, Burke JF. Epidemiology of infections with *Pseudomonas aeruginosa* in burn patients: the role of hydrotherapy. *Clin Infect Dis* 1992 Dec; 15(6):941-9.
 87. Duncan HE, Edberg SC. Host-microbe interaction in the gastrointestinal tract. *Crit Rev Microbiol* 1995; 21(2):85-100.
 88. Moiraghi A, Castellani Pastoris M, Barral C, Carle F, Sciacovelli A, Passarino G, Marforio P. Nosocomial legionellosis associated with use of oxygen bubble humidifiers and underwater chest drains. *J Hosp Infect* 1987 Jul; 10(1):47-50.
 89. Astagneau P, Desplaces N, Vincent V, Chicheportiche V, Botherel A, Maugat S, Lebascle K, Leonard P, Desenclos J, Grosset J, Ziza J, Brucker G. Mycobacterium xenopi spinal infections after discov-ertebral surgery: investigation and screening of a large outbreak. *Lancet* 2001 Sep 1; 358(9283):747-51.
 90. Ferroni A, Nguyen L, Pron B, Quesne G, Brusset MC, Berche P. Outbreak of nosocomial urinary tract infections due to *Pseudomonas aeruginosa* in a paediatric surgical unit associated with tap-water contamination. *J Hosp Infect* 1998 Aug; 39(4):301-7.
 91. Muscarella LF. Application of environmental sampling to flexible endoscope reprocessing: the importance of monitoring the rinse water. *Infect Control Hosp Epidemiol* 2002 May; 23(5):285-9 Review.
 92. Maloney S, Welbel S, Daves B, Adams K, Becker S, Bland L, Arduino M, Wallace R Jr, Zhang Y, Buck G, et al. Mycobacterium abscessus pseudo-infection traced to an automated endoscope washer: utility of epidemiologic and laboratory investigation. *J Infect Dis* 1994 May; 169(5):1166-9.
 93. Alvarado CJ, Stolz SM, Maki DG. Nosocomial infections from contaminated endoscopes: a flawed automated endoscope washer. An investigation using molecular epidemiology. *Am J Med* 1991 Sep 16; 91(3B):272S-80S.
 94. Sethi S, Sharma M, Ray P, Singh M, Gupta A. Mycobacterium fortuitum wound infection following laparoscopy. *Indian J Med Res* 2001 Mar; 113:83-4.
 95. Sniadack DH, Ostroff SM, Karlix MA, Smithwick RW, Schwartz B, Sprauer MA, Silcox VA, Good RC. A nosocomial pseudo-outbreak of *Mycobacterium xenopi* due to a contaminated potable water supply: lessons in prevention. *Infect Control Hosp Epidemiol* 1993 Nov; 14(11):636-41.
 96. Woo AH, Yu VL, Goetz A. Potential in-hospital modes of transmission of *Legionella pneumophila*. Demonstration experiments for dissemination by showers, humidifiers, and rinsing of ventilation bag apparatus. *Am J Med* 1986 Apr; 80(4):567-73.
 97. Wilson IG, Hogg GM, Barr JG. Microbiological quality of ice in hospital and community. *J Hosp Infect* 1997 Jul; 36(3):171-80.
 98. Stamm WE, Colella JJ, Anderson RL, Dixon RE. Indwelling arterial catheters as a source of nosocomial bacteremia. An outbreak caused

- by *Flavobacterium* Species. *N Engl J Med* 1975 May 22;292(21):1099-102.
99. Graman PS, Quinlan GA, Rank JA. Nosocomial legionellosis traced to a contaminated ice machine. *Infect Control Hosp Epidemiol* 1997 Sep;18(9):637-40.
 100. Laussucq S, Baltch AL, Smith RP, Smithwick RW, Davis BJ, Desjardin EK, Silcox VA, Spellacy AB, Zeimis RT, Gruft HM, et al. Nosocomial *Mycobacterium fortuitum* colonization from a contaminated ice machine. *Am Rev Respir Dis* 1988 Oct;138(4):891-4.
 101. Panwalker AP, Fuhse E. Nosocomial *Mycobacterium gordonae* pseudoinfection from contaminated ice machines. *Infect Control* 1986 Feb;7(2):67-70.
 102. Nucci M, Akiti T, Barreiros G, Silveira F, Revankar SG, Wickes BL, Sutton DA, Patterson TF. Nosocomial outbreak of *Exophiala jeanselmei* fungemia associated with contamination of hospital water. *Clin Infect Dis* 2002 Jun 1;34(11):1475-80.
 103. Gomez-Cerezo J, Suarez I, Rios JJ, Pena P, Garcia de Miguel MJ, de Jose M, Monteagudo O, Linares P, Barbado-Cano A, Vazquez JJ. *Achromobacter xylosoxidans* bacteremia: a 10-year analysis of 54 cases. *Eur J Clin Microbiol Infect Dis* 2003 Jun;22(6):360-3.
 104. Engelhart S, Glasmacher A, Kaufmann F, Exner M. Protecting vulnerable groups in the home: the interface between institutions and the domestic setting. *J Infect* 2001 Jul;43(1):57-9.
 105. Ortolano GA, Russell R, Capetandes A, Wenz B. Transfusion-associated Immunosuppression—Heuristic Model or Clinical Concern. *Modern Aspects of Immunobiology* 2002;2(4):159-165 and reprinted by request of the Italian Society of Transfusion Medicine in *Blood Transfusion* 2003;1:47-64 [English and Italian].
 106. Ortolano GA, Russell RL, Angelbeck JA, Schaffer J, Wenz B. Contamination control in nursing with filtration: Part 2: Emerging rationale for bedside (Final) filtration of prestorage leukocyte-reduced blood products. *J Infus Nurs* 2004 May;27(3):157-65.
 107. Microbiological issues available on the internet as of May 17, 2004 at http://www.who.int/water_sanitation_health/dwq/en2edvol11b.pdf.
 108. US EPA website concerning List of Drinking Water Contaminants & MCLs retrieved on May 21, 2004 at website <http://www.epa.gov/safewater/mcl.html#3> and enacted by the Safe Water Drinking Act 1974, amended 1986 and again in 1996 and U.S. Environmental Protection Agency. Drinking Water; national primary drinking water regulations; filtration, disinfection; turbidity, *Giardia lamblia*, viruses *Legionella* and heterotrophic bacteria- final rule. 1989 Fed Regist. 54(124):27485.
 109. Federal-Provincial-Territorial Committee on Drinking Water. Bacteriological Quality In Guidelines for Canadian Drinking Water Quality: Supporting Documentation 2002;1-17.
 110. Water Supply (Water Quality) Regulations 2000 (England) and the Water Supply (Water Quality) Regulations 2001 (Wales) DWI Drinking Water Inspectorate September 2003 and Council Directive 98/83/EC of 3 November 1998 on the quality of water intended for human consumption.
 111. Bellillo (il Presidente), Carpani (il segretario), Linea—Guida per la prevenzione e il controllo della legionellosi. *Giornale Italiano della Infezioni Ospedaliere* 2000;7(3):118-32.
 112. DVGW- Deutscher Verein des Gas-und Wasserfaches e.V. Technische regel Arbeitsblatt W552 April 1996.
 113. Retained from internet on May 17, 2004, at <http://www.drinkingwaterseminar.org/>.
 114. Drinking water Standards for New Zealand 2000 Ministry of Health reference website: Ministry of Health's Web site: <http://www.moh.govt.nz>.
 115. JCAHO. Surveillance, prevention and control of infection 2005 Pre-publication Edition—Infection Control HAP Prepublication Copy Retrieved on May 17, 2004 from web-site http://www.jcaho.org/accredited+organizations/patient+safety/infection+control/05_ic_std_hap.pdf.
 116. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJ. Bacterial biofilms in nature and disease. *Ann Rev. Microbiol* 1987;41:435-64.
 117. De Beer D, Stoodley P, Roe F, Lewandowski Z. Effects of biofilm structures on oxygen distribution and mass transport. *Biotech. Bioeng* 1994;43:1131-8.
 118. Patterson MK, Husted GR, Rutowski A, Mayette DC. Isolation, identification and microscopic properties of biofilms in high-purity water distribution systems. *Ultrapure Water* 1991;8(4):18-23.
 119. Lawrence JR, Korber DR, Hoyle BD, Costerton JW, Caldwell DE. Optical sectioning of microbial biofilms. *J. Bacteriol* 1991;173(20):6558-67.
 120. Costerton JW. Structure of biofilms. In: Geesey GG, Lewandowski Z, Flemming HC, editors. *Biofouling and Biocorrosion in industrial water systems*. Lewis Publishers; 1997. p. 3-14.
 121. Allison DG. Exopolysaccharide production in bacterial biofilms. *Biofilm* 1998;3(2): retrieved on the internet on May 21, 2004 <http://www.bioline.org.br/request?bf98002>.
 122. Gantzer CJ, Cunningham AB, Gujer W, Gutekunst B, Heijnen JJ, Lightfoot EN, Odham G, Rittman BE, Rosenberg E, Stolzenbach KD, Zehnder AJB. Exchange processes at the fluid-biofilm interface. In: Characklis WG, Wilderer PA, editors. *Structure and function of biofilms*. John Wiley & Sons; 1989. p. 73-89.
 123. Ramage G, VandeWalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by *Candida albicans*. *Rev Iberoam Micol* 2001;18:163-70.
 124. Lejeune P. Contamination of abiotic surfaces: what a colonizing bacterium sees and how to blur it. *Trends Microbiol* 2003 Apr;11(4):179-84.
 125. Costerton JW, Lappin-Scott HM. Behavior of bacteria in biofilms. *ASM News* 1989;55:650-4.
 126. Gilbert P, Evals DJ, Brown MRW. Formation and dispersal of bacterial biofilms in vivo and in situ. *J Appl Bact Symp Suppl* 1993; 74:67S-78S.
 127. McLean RJ, Whiteley M, Stickler DJ, Fuqua WC. Evidence of autoinducer activity in naturally occurring biofilms. *FEMS Microbiol Lett* 1997;154(2):259-63.
 128. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 1998;280:295-8.
 129. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, Rice SA, Eberl L, Molin S, Hoiby N, Kjelleberg S, Givskov M. Inhibition of quorum sensing in *Pseudomonas aeruginosa* biofilm bacteria by a halogenated furanone compound. *Microbiology* 2002; 148:87-102.
 130. Labbate M, Queck SY, Koh KS, Rice SA, Givskov M, Kjelleberg S. Quorum sensing-controlled biofilm development in *Serratia liquefaciens* MG1. *J Bacteriol* 2004;186(3):692-8.
 131. Federle MJ, Bassler BL. Interspecies communication in bacteria. *J Clin Invest* 2003;112:1291-9.
 132. Costerton JW, Stewart PS, Greenberg P. Bacterial biofilms: A common cause of persistent infections. *Science* 1999;284:1318-22.
 133. Costerton JW, Lewandowski Z, DeBeer D, Caldwell D, Korber D, James G. Biofilms, the customized niche. *J Bacteriol* 1994;176(8):2137-42.
 134. Sauer K, Camper AK. Characterization of phenotypic changes in *Pseudomonas putida* in response to surface-associated growth. *J Bacteriol* 2001;183(22):6579-89.
 135. Dunne WM. Bacterial adhesion: seen any good biofilms lately? *Clin. Microbiol. Reviews* 2002;15(2):155-66.
 136. Costerton JW, Geesey GG & Cheng KJ (1978). How bacteria stick. *Scientific American*, 1978;238:86-95.

137. Costerton JW. Structure of biofilms. In: Geesey GG, Lewandowski Z, Flemming HC, editors. *Biofouling and Biocorrosion in industrial water systems*. Lewis Publishers; 1997. p. 3-14.
138. Keevil CW, Mackerness CW, Colbourne JS. Biocide treatment in biofilms. *Int Biodeterioration* 1990;26:169-70.
139. Anwar H, Strap JL. Changing characteristics of aging biofilms. *Int Biodeter Biodeg* 1992;30:177-86.
140. Sanford BA, de Feijter AV, Wade MH, Thomas VL. A dual fluorescence technique for visualization of *Staphylococcus epidermidis* biofilm using scanning confocal laser microscopy. *J Ind Microbiol* 1996;16:48-56.
141. Lewis K. Riddle of biofilm resistance. *Antimicrob Agents Chemotherapy* 2001;45(4):999-1007.
142. Watnick P, Kolter R. Biofilm, city of microbes. *J Bacteriol* 2000;182(10):2675-9.
143. Hausner M, Wuertz S. High rates of conjugation in bacterial biofilms as determined by quantitative in situ analysis. *Appl Environ Microbiol* 1999;65(8):3710-3.
144. Yu FP, Pyle BH, McFeters GA. A direct viable count method for the enumeration of attached bacteria and assessment of biofilm disinfection. *J Microbiol Methods* 1993 Apr;17(3):167-80.
145. Ollos PJ, Huck PM, Slawson R. Factors affecting biofilm accumulation in model distribution systems. *JAWWA* 2003;95(1):87-97.
146. Lin YE, Vidic RD, Stout JE, Yu VL. Negative effect of high pH on biocidal efficacy of copper and silver ions in controlling *Legionella pneumophila*. *Appl Environ Microbiol* 2002;68(6):2711-5.
147. Wadowsky RM, Yee RB, Mezmar L, Wing EJ, Dowlink JN. Hot water systems as sources of *Legionella pneumophila* in hospital and nonhospital plumbing fixtures. *Appl Environ Microbiol* 1982;43(5):1104-10.
148. Martyak JE, Carmody JC, Husted GR. Characterizing biofilm growth in deionized ultrapure water piping systems. *Microcontamination* 1993 Jan;11(1):39-44.
149. McFeters GA, Broadaway SC, Pyle BH, Egozy Y. Distribution of bacteria within operating laboratory water purification systems. *Appl Environ Microbiol* 1993 May;59(5):1410-5.
150. Riedewald F. Biofilms in pharmaceutical water. *Pharm Eng* 1997 Nov/Dec;17(6):8-19.
151. Emtiaz F, Schwartz T, Marten SM, Krolla-Sidenstein P, Obst U. Investigation of natural biofilms formed during the production of drinking water from surface water embankment filtration. *Water Res* 2004;38:1197-206.
152. Horowitz A, Krichevsky MI, Atlas RM. Characteristics and diversity of subarctic marine oligotrophic, stenoheterotrophic, and euryheterotrophic bacterial populations. *Can J Microbiol* 1983;29:527-35.
153. Roszak DB, Colwell RR. Survival strategies of bacteria in the natural environment. *Microbiol Rev* 1987 Sep;51(3):365-79.
154. Poindexter JS. Oligotrophy; fast and famine existence. *Adv Microbiol Ecol* 1981;5:63-89.
155. Rittmann BE, Crawford L, Tuck CK, Namkung E. In situ determination of kinetic parameters for biofilms; isolation and characterization of oligotrophic biofilms. *Biotech Bioeng* 1986;28:1753-60.
156. Kuznetsov SI, Dubinina GA, Lapteva NA. Biology of oligotrophic bacteria. *Ann Rev Microbiol* 1979;33:377-87.
157. Wainwright M, Adam Ali T, Barakah F. A review of the role of oligotrophic microorganisms in biodeterioration. *Int Biodeter Biodeg* 1993;31:1-13.
158. Riedewald F. Biofilms in pharmaceutical water. *Pharm Eng* 1997 Nov/Dec;17(6):8-19.
159. Reasoner DJ, Geldreich EE. A new medium for the enumeration and subculture of bacteria from potable water. *Appl Environ Microbiol* 1985;49(1):1-7.
160. Lombardo LR, West PR & Holbrook JL. A comparison of various media and incubation temperatures used in the heterotrophic plate count analysis. *Proceedings of the Water Quality Technology Conference, Portland, Oregon, Nov 16-20, 1986*:251-69.
161. Gibbs RA, Hayes CR. The use of R2A medium and the spread plate method for the enumeration of heterotrophic bacteria in drinking water. *Lett Appl Microbiol* 1988;6:19-21.
162. Williams HN, Quinby H, Romberg E. Evaluation and use of a low nutrient medium and reduced incubation temperature to study bacterial contamination in the water supply of dental units. *Can J Microbiol* 1994;40:127-31.
163. Camper AK, McFeters GA. Problems of biofouling in drinking water systems. In: Walker J, Surman S, Jass J, editors. *Industrial Biofouling*. John Wiley & Sons Ltd; 2000. p. 15-54.
164. Clancy JL, Cimini L. Microbes. Improved methods for recovering bacteria from HPW. *Ultrapure Water* 1991 May/June;8(4):25-37.
165. Delahaye E, Welte B, Levi Y, Leblon G, Montiel A. An ATP-based method for monitoring the microbiological drinking water quality in a distribution network. *Water Res* 2003;37(15):3689-96.
166. Huang CT, Yu FP, McFeters GA, Stewart PS. Nonuniform spatial patterns of respiratory activity within biofilms during disinfection. *Appl Environ Microbiol* 1995;61(6):2252-6.
167. Emtiaz F, Schwartz T, Marten SM, Krolla-Sidenstein P, Obst U. Investigation of natural biofilms formed during the production of drinking water from surface water embankment filtration. *Water Res* 2004;38:1197-206.
168. Kalmbach S, Manz W, Szweduk U. Dynamics of biofilm formation in drinking water: phylogenetic affiliation and metabolic potential of single cells assessed by formazan reduction and in situ hybridization. *FEMS Micro Ecol* 1997;22:265-79.
169. MacDonald WD, Pelletier CA, Gasper DL. Practical methods for the microbial validation of sterilizing-grade filters used in aseptic processing. *J Parenter Sci Technol* 1989 Nov-Dec;43(6):266-70.
170. Sundaram S, Eisenhuth J, Howard G Jr, Brandwein H. Retention of water-borne bacteria by membrane filters. Part I: Bacterial challenge tests on 0.2 and 0.22 micron rated filters. *PDA J Pharm Sci Technol* 2001 Mar-Apr;55(2):65-86.
171. Sehulster L, Chinn RY, CDC, HICPAC. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep* 2003 Jun 6;52(RR-10):1-42.
172. Hummel M, Kurzuk M, Hetzer R. Prophylactic and pre-emptive strategies for control of Legionnaires disease in heart transplant recipients. Abstract P761 from Deutsches Herzzentrum; Berlin, Germany from the 9th European Congress of Clinical Microbiology and Infectious Diseases held in Berlin March 21-24, 1999.
173. Engelhart S, Krizek L, Glasmacher A, Fischnaller E, Marklein G, Exner M. *Pseudomonas aeruginosa* outbreak in a haematology-oncology unit associated with contaminated surface cleaning equipment. *J Hosp Infect* 2002 Oct;52(2):93-8.
174. Vonberg R, Bruderek J, Gastmeier P. Use of terminal tap water filters systems for nosocomial *Legionellosis* prevention. *Poster abstract presented at the Fourteenth Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA)*; April 18, 2004; Philadelphia, PA (Abstract #191).
175. Ortolano GA, Russell RL, Angelbeck JA, Schaffer J, Wenz B. Contamination control in nursing with filtration: Part I: filters applied to intravenous fluids and point-of-use hospital water. *J Infus Nurs* 2004 Mar-Apr;27(2):89-103.
176. Sharma S, Sachdeva P, Virdi JS. Emerging water-borne pathogens. *Appl Microbiol Biotechnol* 2003 Jun;61(5-6):424-8.
177. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2004 Feb;2(2):95-108.

178. Alcon A, Fabregas N, Torres A. Hospital-acquired pneumonia: etiologic considerations. *Infect Dis Clin North Am* 2003 Dec;17(4): 679-95.
179. Huang DB, Okhuysen PC, Jiang ZD, DuPont HL. Enteroggregative *Escherichia coli*: an emerging enteric pathogen. *Am J Gastroenterol* 2004 Feb;99(2):383-9.
180. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. *Emerg Infect Dis* 2004 Jan;10(1):14-9.
181. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on *Pseudomonas aeruginosa*. *Chest* 2004 Feb; 125(2 Suppl):62S-9S.
182. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. *J Clin Invest* 2003 Nov;112(9):1300-7.
183. Exner M, Kistemann T. Significance of the Ordinance on the Quality of Water for Human Consumption. *Trinkwasserverordnung 2001—Drinking water Ordinance (DWVO) 2001*.
184. France Gov't Guidelines. Relative to the Prevention of Risks Linked to *Legionella* in Health Establishments DGS/SD7A/SD5C/E4 No. 2002/243 of 22/04/02 Guidelines.
185. Christensen BE, Characklis WG. Physical and chemical properties of biofilms. In: Characklis WG, Marshall KC, editors. *Biofilms*. New York: John Wiley & Sons, Inc.; 1990. p. 93-130.
186. Sutherland IW. Biofilm exopolysaccharides: a strong and sticky framework. *Microbiology* 2001;147:3-9.
187. LeChevallier MW, Schulz W, Lee RG. Bacterial nutrients in drinking water. *Appl Environ Microbiol* 1991;57(3):857-62.
188. Stoodley P, Lewandowski Z, Boyle JD, Lappin-Scott HM. The formation of migratory ripples in a mixed species bacterial biofilm grown in turbulent flow. *Environ Microbiol* 1999;1(5):447-55.
189. Geldreich G. *Biofilms in water distribution systems*. NY: CRC Press; 1996. p. 159-214.
190. LeChevallier MW, Babcock TM, Lee RG. Examination and characterization of distribution system biofilms. *Appl Environ Microbiol* 1989;53(12):2714-24.
191. Bagh LK, Albrechtsen HJ, Arvin E, Ovesen K. Biofilm formation in a hot water system. *Water Sci Technol* 2002;46(9):95-101.
192. Rittman BE. Detachment from biofilms. In: Characklis WG, Wilderer PA, editors. *Structure and function of biofilms*. John Wiley & Sons; 1989. p. 49-58.
193. Bott TR. The use of biocides in industry. In: Melo LF, Bott TR, Fletcher M, Capdeville B, editors. *Biofilms – Science and Technology*. Kluwer Academic Publishers; 1992. p. 567-81.
194. Le Dantec C, Duguet JP, Montiel A, Dumoutier N, Dubrou S, Vincent V. Chlorine disinfection of atypical *Mycobacteria* isolated from a water distribution system. *Appl Environ Microbiol* 2002;68(3): 1025-32.
195. Williams MM, Braun-Howland EB. Growth of *Escherichia coli* in model distribution system biofilms exposed to hypochlorous acid or monochloramine. *Appl Environ Microbiol* 2003 Sept;69(9): 5463-71.
196. Kilvington S, Price J. Survival of *Legionella pneumophila* within cysts of *Acanthamoeba polyphaga* following chlorine exposure. *J Appl Bacteriol* 1990 May;68(5):519-25.
197. Smith AJ, Bagg J, Hood J. Use of chlorine dioxide to disinfect dental unit waterlines. *J Hosp Infect* 2001 Dec;49(4):285-8.
198. Walker JT, Mackerness CV, Mallon D, Makin T, Williets T, Keevil CW. Control of *Legionella pneumophila* in a hospital water system by chlorine dioxide. *J Ind Microbiol* 1995 Oct;15(4):384-90.
199. Taylor RH, Falkinham JO 3rd, Norton CD, LeChevallier MW. Chlorine, chloramine, chlorine dioxide, and ozone susceptibility of *Mycobacterium avium*. *Appl Environ Microbiol* 2000 Apr;66(4): 1702-5.
200. Neilan BA, Ehlers SM, Kolpin CF, Eaton JW. Prevention of chloramine-induced hemolysis in dialyzed patients. *Clin Nephrol* 1978 Sep; 10(3):105-8.
201. DeTorres JP, Strom JA, Jaber BL, Hendra KP. Hemodialysis-associated methemoglobinemia in acute renal failure. *Am J Kidney Dis* 2002 Jun; 39(6):1307-9.
202. Kusnetsov J, Iivanainen E, Elomaa N, Zacheus O, Martikainen PJ. Copper and silver ions more effective against legionellae than against mycobacteria in a hospital warm water system. *Water Res* 2001 Dec; 35(17):4217-25.
203. Szewzyk R, Szewzyk U, Manz W, Schleifer KH. Microbiological safety of drinking water. *Ann. Rev. Microbiol* 2000;54:81-127.
204. Chamberlain AHL. The role of adsorbed layers in bacterial adhesion. In: Melo LF, Bott TR, Fletcher M, Capdeville B, editors. *Biofilms—Science and Technology*. Kluwer Academic Publishers; 1992. p. 59-67.
205. Van Loosdrecht MCM, Lyklema J, Norde W, Zehnder AJB. Influence of interfaces on microbial activity. *Microbiol. Reviews* 1990;54(1): 75-87.
206. Costerton JW, Stewart PS. Battling biofilms. *Scientific American* 2001 July;75-81.
207. Stanley C & Bayston R. Use of "antimicrobial" polymers to prevent device-related infections. In: *Biofilms; The good, the bad and the ugly*. Wimpenny J, Golbert P, Walker J Brading M & Bayston R (eds). Bioline UK, 1999:65-71.